Stevanato Group (STVN) Competitors

Zimmer Biomet (NYSE:ZBH) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk.

Do institutionals & insiders hold more shares of ZBH or STVN?

88.9% of Zimmer Biomet shares are owned by institutional investors. 1.0% of Zimmer Biomet shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has better valuation and earnings, ZBH or STVN?

Zimmer Biomet has higher revenue and earnings than Stevanato Group. Zimmer Biomet is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.68B	2.89	$903.70M	$4.45	25.01
Stevanato Group	$1.10B	6.13	$157.62M	$0.48	46.54

Does the MarketBeat Community favor ZBH or STVN?

Zimmer Biomet received 874 more outperform votes than Stevanato Group when rated by MarketBeat users. Likewise, 67.06% of users gave Zimmer Biomet an outperform vote while only 62.50% of users gave Stevanato Group an outperform vote.

Company	Underperform	Outperform
Zimmer Biomet	Outperform Votes 904 67.06%	Underperform Votes 444 32.94%
Stevanato Group	Outperform Votes 30 62.50%	Underperform Votes 18 37.50%

Does the media prefer ZBH or STVN?

In the previous week, Zimmer Biomet had 17 more articles in the media than Stevanato Group. MarketBeat recorded 26 mentions for Zimmer Biomet and 9 mentions for Stevanato Group. Zimmer Biomet's average media sentiment score of 1.37 beat Stevanato Group's score of 1.13 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	22 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, ZBH or STVN?

Zimmer Biomet has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.

Do analysts rate ZBH or STVN?

Zimmer Biomet currently has a consensus target price of $124.15, indicating a potential upside of 11.54%. Given Zimmer Biomet's higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	11 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.32
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Is ZBH or STVN a better dividend stock?

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 0.9%. Stevanato Group pays an annual dividend of €0.06 per share and has a dividend yield of 0.3%. Zimmer Biomet pays out 21.6% of its earnings in the form of a dividend. Stevanato Group pays out 12.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Is ZBH or STVN more profitable?

Zimmer Biomet has a net margin of 11.77% compared to Stevanato Group's net margin of 10.47%. Zimmer Biomet's return on equity of 12.99% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	11.77%	12.99%	7.58%
Stevanato Group	10.47%	9.86%	5.79%

Summary

Zimmer Biomet beats Stevanato Group on 16 of the 20 factors compared between the two stocks.